The hearing loss treatment developer has raised more than $127m in its initial public offering that offered exits to Alphabet, GlaxoSmithKline and Regeneron.
Decibel Therapeutics, a US-based hearing loss drug developer backed by corporates Alphabet, GlaxoSmithKline (GSK) and Regeneron, priced its shares at $18 to raise more than $127m in its IPO on the Nasdaq Global Select Market on Thursday. The company issued slightly more than 7 million shares and beat its original target of $75m. Shares briefly…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.